-

Bayer Statement on Win in Jones Roundup™ Trial

WHIPPANY, N.J.--(BUSINESS WIRE)--On Friday, December 22, a jury reached a defense verdict in the Jones Roundup™ product liability trial before Judge Patrick Palacios in the Superior Court of California, San Benito County, and the Company issued the following statement.

“The jury’s verdict in favor of the Company brings this trial to a successful conclusion and is consistent with the evidence in this case that Roundup™ does not cause cancer and is not responsible for the plaintiff’s illness. The verdict continues the Company’s strong record at trial, winning ten of the last fifteen cases, and validates its strategy of taking cases to trial based on the overwhelming weight of scientific and consistent worldwide regulatory support for the safety of these products.

“We continue to stand behind the safety of Roundup™ and will continue to confidently defend the safety of our products and our good faith actions in future litigation.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Social Media Channels
- Facebook: BayerUnitedStates
- Twitter: BayerUS
- Instagram: BayerUS
- YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Contacts

Nicole Hayes
Director, U.S. External Communications
Nicole.Hayes@Bayer.com
(201) 421-5268

Bayer


Release Versions

Contacts

Nicole Hayes
Director, U.S. External Communications
Nicole.Hayes@Bayer.com
(201) 421-5268

More News From Bayer

Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation

LEVERKUSEN--(BUSINESS WIRE)--The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circuit courts on the application of federal preemption, a cross-cutting issue in the Roundup™ litigation. The company expects a decision on the merits during the Court’s 2026 session, which ends in June. “The Supreme Court decision to take the case is good news for U.S. far...

Bayer Accelerates Pharma Growth on High-Value Portfolio

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...

Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn’t Stop for a Hot Flash’ campaign, which speaks to women with moderate to severe hot flashes due to menopause. The campaign encourages women to have an open and honest conversation with their healthcare provider about their hot flash experiences and learn about treatment options, including Lynkuet® (elinzanetant) 60mg capsules, a hormone-free prescri...
Back to Newsroom